Detection of mutations in the BRAF in patients with melanoma in routine clinical practice: Survey results
- 作者: Orlova K.1, Demidov L.1
-
隶属关系:
- Blokhin National Medical Research Center of Oncology
- 期: 卷 26, 编号 1 (2024)
- 页面: 36-38
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/258571
- DOI: https://doi.org/10.26442/18151434.2024.1.202630
- ID: 258571
如何引用文章
全文:
详细
Background. According to current clinical guidelines, patients with inoperable and/or metastatic melanoma (IMM) should undergo a molecular genetic study for the presence of mutations in the BRAF V600 gene in order to select drug therapy. Its accessibility and timing may vary in the regions of Russia.
Aim. To assess the possibility, accessibility, and timing of a molecular genetic study for melanoma in Russia.
Results. From November 15, 2023, to December 11, 2023, a survey was conducted, which included 32 respondents (oncologists and heads of depart- ments/laboratories) from various federal districts, where 1 to 1000 IMM patients are being diagnosed and treated annually. A mutation in the BRAF gene was detected in 79,1% of patients. The duration of the study was about 15 (3-35) days. The mutations were detected in a local institution in 60% of cases, within the Russian Society of Clinical Oncology diagnostic program in 21,1%, and in other programs in 18,9%.
Conclusion. The wide accessibility of the detection of BRAF gene mutations in the Russian Federation was reported due to the following factors: the introduction of molecular genetic diagnostics programs, in particular the Russian Society of Clinical Oncology program, as well as other programs sponsored by pharmaceutical companies and the possibility of testing under a compulsory health insurance policy. However, approximately 21% (20,9%) of patients with IMM do not test for mutations in the BRAF gene, even if they have their own laboratory in the institution. It is crucial to test all patients with melanoma from stage III onwards for BRAF mutations, especially when treatment is started with immunotherapy and there is enough time for the BRAF mutation result to be routinely obtained.
作者简介
Kristina Orlova
Blokhin National Medical Research Center of Oncology
编辑信件的主要联系方式.
Email: krisman03@gmail.com
ORCID iD: 0000-0002-0442-5917
Cand. Sci. (Med.)
俄罗斯联邦, MoscowLev Demidov
Blokhin National Medical Research Center of Oncology
Email: krisman03@gmail.com
ORCID iD: 0000-0002-8562-6082
D. Sci. (Med.), Prof.
俄罗斯联邦, Moscow参考
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. doi: 10.1038/nature00766
- AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818-31. doi: 10.1158/2159-8290.CD-17-0151
- Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023;8(2):100788. doi: 10.1016/j.esmoop.2023.100788
- Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666):234-8. doi: 10.1038/nature23291
- Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183-99. doi: 10.1038/s41388-018-0171-x
- Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329-41. doi: 10.1158/2159-8290.CD-18-1321
- Dankner M, Wang Y, Fazelzad R, et al. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO Precis Oncol. 2022;6: e2200107. doi: 10.1200/PO.22.00107
- Elder DE, Massi D, Scolyer RA, Willemze R. WHO Classification of Skin Tumours. 4th ed. France, Lyon: International Agency for Research on Cancer, 2018.
- Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175-80.
- Castillo P, Marginet M, Jares P, et al. Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. Explor Target Antitumor Ther. 2020;1(2):101-8. doi: 10.37349/etat.2020.00006
- Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327
- Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-23. doi: 10.1002/cncr.26724
- Cheng S, Chu P, Hinshaw M, et al. Frequency of mutations associated with targeted therapy in malignant melanoma patients. J Clin Oncol. 2011;29(15). doi: 10.1200/jco.2011.29.15_suppl.8597
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. doi: 10.1056/NEJMoa1103782
- Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4
- Seth R, Agarwala SS, Messersmith H, et al. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023;41(30):4794-820. doi: 10.1200/JCO.23.01136
- Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435-48. doi: 10.1016/j.annonc.2020.07.004
- Строяковский Д.Л., Абдулоева Н.Х., Демидов Л.В., и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли: практические рекомендации RUSSCO. 2023;13:291-310 [Stroyakovsky DL, Abduloeva NKh, Demidov LV, et al. Practical guidelines for drug treatment of skin melanoma. Malignant Tumours: RUSSCO Practical Guidelines. 2023;13:291-310 (in Russian)]. doi: 10.18027/2224-5057-2023-13-3s2-1–291-310
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2022. Eur J Cancer. 2022;170:256-84. doi: 10.1016/j.ejca.2022.04.018